Digest Réseau Comment ça marche
Réseau
/
Sociétés
Sa
Non vérifié

Santhera Pharmaceuticals Holding AG

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologiePublicité/Marketing/Médias/Communication

33 communiqués de presse

Voir tous les communiqués de presse
09/02/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Appoints Stifel as Corporate Finance Advisor
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
14/01/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
07/01/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
04/11/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Closes USD 13 Million Royalty Monetization Agreement
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
08/10/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
02/10/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
24/09/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
22/09/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0